[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368258-105":59,"doc-detail-368258-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prevalence-of-constitutional-pathogenic-variant-in-a-cohort-of-348-patients-with-multiple-primary-cancer-addressed-in-oncogenetic-consultation","Prevalence of Constitutional Pathogenic Variant in a Cohort of 348 Patients With Multiple Primary Cancer Addressed in Oncogenetic Consultation","","Study evaluates the prevalence of constitutional pathogenic or likely pathogenic germline variants in patients undergoing oncogenetic consultation for multiple primary malignancies (MPMs). From 2010–2022, 348 patients with at least two primary cancers were compared with 1422 patients with a single primary cancer using a panel up to 47 cancer predisposition genes. Pathogenic/likely pathogenic variants were detected in 27.3% of MPM cases versus 11.39% in single-cancer controls, with higher detection when cancers match a suspected syndrome.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prevalence-of-constitutional-pathogenic-variant-in-a-cohort-of-348-patients-with-multiple-primary-cancer-addressed-in-oncogenetic-consultation/368258/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prevalence-of-constitutional-pathogenic-variant-in-a-cohort-of-348-patients-with-multiple-primary-cancer-addressed-in-oncogenetic-consultation/368258.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of this oncogenetic consultation study?","Question",{"text":112,"@type":113},"To assess the value of genetic testing for patients with multiple primary cancers by estimating the prevalence of constitutional pathogenic variants.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were participants selected and compared?",{"text":117,"@type":113},"Families were seen from 2010 to 2022, and patients with at least two primary cancers (n=348) were compared with patients with a single primary cancer (n=1422) using a panel of up to 47 predisposition genes.",{"name":119,"@type":110,"acceptedAnswer":120},"What detection rates were found for pathogenic or likely pathogenic variants?",{"text":121,"@type":113},"A pathogenic or likely pathogenic variant was diagnosed in 27.3% of the 348 MPM patients versus 11.39% in the single-cancer group. Detection increased further to 36% when the multiple cancers pertained to the same predisposition syndrome.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368258,1790548466,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Molecular Genetics & Genomic Medicine  \nORIGINAL ARTICLE  OPEN ACCESS   \nPrevalence of Constitutional Pathogenic Variant in a Cohort of 348 Patients With Multiple Primary Cancer Addressed in Oncogenetic Consultation  \nMathis Lepage1,2  | Nancy Uhrhammer1,2 | Ioana Molnar3 | Maud Privat1,2  | Flora Ponelle-Chachuat1,2 | Mathilde Gay-Bellile1,2 | Yannick Bidet1,2 | Mathias Cavaillé1,2,4  \n1Département d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France | 2INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Université Clermont Auvergne, Clermont-Ferrand, France | 3Division de Recherche Clinique, Délégation Recherche Clinique & Innovation, Centre Jean  \nPERRIN, Clermont-Ferrand, France | 4Département d'Oncogénétique, CHU de Québec–Université Laval, Quebec, Canada Correspondence: Mathis Lepage ([mathis.lepage@clermont.unicancer.fr](mathis.lepage@clermont.unicancer.fr))  \nReceived: 23 October 2024 | Revised: 14 February 2025 | Accepted: 21 February 2025  \nFunding: The authors received no specific funding for this work.  \nKeywords: genetic testing | germline | multiple primary cancer  \nABSTRACT  \nIntroduction: Multiple primary malignancies (MPMs) refer to two or more primary malignant tumors in the same patient. MPMs are frequent: 18.4% of incident cancers represent a second or a higher primary cancer. In order to assess the value of genetic testing for patients with multiple cancers, studies are needed to accurately determine the prevalence of pathogenic variants for these patients.  \nMethods: All families were seen in our oncogenetics consultation from 2010 to 2022. We compared clinical features and detection rates of pathogenic or likely pathogenic variants in a panel of up to 47 cancer predisposition genes in patients with ≥2 primary cancers (n = 348) versus a single primary cancer (n = 1422) .  \nResults: A pathogenic or likely pathogenic variant was diagnosed in 27.3% of patients with 348 index patients with MPM, concerning 21 genes: BRCA1 (n = 27), BRCA2 (n = 19), MSH2 (n = 9), ATM (n = 8), MLH1 (n = 5), MSH6 (n = 6), TP53 (n = 4), CHEK2 (n = 4), PALB2 (n = 3), APC (n = 2), MEN1 (n = 1), RAD51C (n = 1), NBN (n = 1), EPCAM (n = 1), PMS2 (n = 1), RB1 (n = 1), PTEN (n = 1), CYLD1 (n = 1), NF1 (n = 1), RAD51D (n = 1), and CDKN2A (n = 1). MPM index cases were more likely to carry a deleterious mutation than cases with a single cancer (27.3% vs. 11.39%, p \u003C 0.001) . Pathogenic variants were found more frequently inpatients with a suggestive family history (34.2% vs. 20.1%, p \u003C 0.05), with a younger age of cancer diagnosis related to the suspected syndrome (32.7% vs. 22%, p = 0.049) . For the 208 index patients with ≥2 cancers pertaining to the same predisposition syndrome (HBOC, HNPCC…), the detection rate increased significantly to 36%(vs. 14.3% for MPM patients with unrelated cancers (n = 140), p \u003C 0.001). Conversely, the detection rate for patients with unrelated cancers was not statistically different from the single-cancer population (14.3%–11.39%, p = 0.318) .  \nConclusion: Patients referred for oncogenetic testing with MPM are more likely to carry pathogenic variants in cancer predisposition genes than patients with a single primary cancer (p \u003C 0.05), especially if the cancers are related to the same predisposition syndrome. If the cancers are unrelated, no statistical difference in comparison to the single-cancer population was observed. For these latter patients, we recommend using the specific criteria of each tumor to propose appropriate genetic testing.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Author(s). Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.  \nMolecular Genetics & Genomic Medicine, 2025; 13:e70086 1 of 8  \n[https://doi.org/10.1002/mgg3.70086](https://doi.org/10.1002/mgg3.70086)  \n1 | Introdu","cbCaih5XmISha5Is","https://ap.wps.com/l/cbCaih5XmISha5Is","pdf",486474,"English","# Abstract\n## Introduction\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What was the main goal of this oncogenetic consultation study?\",\"answer\":\"To assess the value of genetic testing for patients with multiple primary cancers by estimating the prevalence of constitutional pathogenic variants.\"},{\"question\":\"How were participants selected and compared?\",\"answer\":\"Families were seen from 2010 to 2022, and patients with at least two primary cancers (n=348) were compared with patients with a single primary cancer (n=1422) using a panel of up to 47 predisposition genes.\"},{\"question\":\"What detection rates were found for pathogenic or likely pathogenic variants?\",\"answer\":\"A pathogenic or likely pathogenic variant was diagnosed in 27.3% of the 348 MPM patients versus 11.39% in the single-cancer group. Detection increased further to 36% when the multiple cancers pertained to the same predisposition syndrome.\"}]","Prevalence of Constitutional Pathogenic Variant in a Cohort of 348 Patients With Multiple Primary Cancer Addressed in Oncogenetic Consultation | PDF",1790175894,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e3d02cc4f876a5f89d746ea1a5b65bb.webp",983,1291,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e809adbb966b7e4b6b5ddf262e49e54f.webp",982,1290,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8898ccb49b9d934b784ac4ae5667a52.webp",981,1289,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/767ce1497b92b55587686d9bfc95af27.webp",980,1287]